The main functions and functions of serputinib/serpatinib capsules

Selpercatinib is a new type of targeted therapy drug, mainly used to treat cancers with RET gene mutations or rearrangements. RET (rearranged transforming factor) gene mutations and rearrangements are drivers of certain cancers, including non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), and thyroid cancer (TC). wait.塞普替尼通过靶向抑制RET基因的异常信号传导，能够有效地减缓或阻止这些癌细胞的生长和扩散。

塞普替尼在治疗RET基因突变的非小细胞肺癌（NSCLC）患者中表现出显著的疗效。 For patients with advanced or metastatic non-small cell lung cancer with RET rearrangement, seputinib can significantly improve the treatment response rate and prolong progression-free survival (PFS), thereby improving the patient's quality of life. In addition, seputinib also shows excellent efficacy in patients with medullary thyroid carcinoma (MTC) caused by RET gene mutations, and can effectively control tumor growth.

The main mechanism of this drug is to inhibit the proliferation and migration of tumor cells by selectively inhibiting the tyrosine kinase activity of the RET receptor. Studies have shown that seputinib has shown good efficacy in clinical trials, especially in the treatment of cancer patients with RET gene mutations. Its significant efficacy makes it an important drug for the treatment of such patients.

In general, seputinib is a targeted drug targeting RET gene mutations or rearrangements, and is suitable for the treatment of non-small cell lung cancer, medullary thyroid cancer and other types of cancer. It effectively slows down the growth and spread of tumors by inhibiting abnormal signaling by RET receptors, providing new treatment options for patients with these specific gene mutations.

Reference:https://en.wikipedia.org/wiki/Selpercatinib